{
    "2019-03-28": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Achillion Completes Enrollment in Rare Blood Disorder Study",
                "features": {
                    "keywords": [
                        "Achillion",
                        "enrollment",
                        "rare blood disorder",
                        "study"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-04-25",
                "original_text": "Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?",
                "features": {
                    "keywords": [
                        "Aerie",
                        "improves",
                        "YTD",
                        "momentum",
                        "sustain"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-07",
                "original_text": "AbbVie's big acquisition blowup: A one-off or an omen?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "acquisition",
                        "blowup",
                        "one-off",
                        "omen"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-03-26",
                "original_text": "Novartis (NVS) Receives FDA Approval for MS Drug Mayzent",
                "features": {
                    "keywords": [
                        "Novartis",
                        "FDA",
                        "approval",
                        "MS drug",
                        "Mayzent"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}